Potomac Capital Management Inc. bought a new stake in shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,010,000 shares of the company’s stock, valued at approximately $3,252,000. Gain Therapeutics comprises about 2.6% of Potomac Capital Management Inc.’s holdings, making the stock its 10th biggest position. Potomac Capital Management Inc. owned about 2.63% of Gain Therapeutics at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of GANX. Geode Capital Management LLC grew its holdings in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares during the last quarter. Marshall Wace LLP grew its holdings in Gain Therapeutics by 41.0% during the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after buying an additional 80,407 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Gain Therapeutics during the 3rd quarter valued at $28,000. JPMorgan Chase & Co. acquired a new stake in Gain Therapeutics during the 3rd quarter valued at $47,000. Finally, Squarepoint Ops LLC acquired a new stake in Gain Therapeutics during the 3rd quarter valued at $68,000. Institutional investors and hedge funds own 11.97% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have commented on GANX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gain Therapeutics in a report on Friday, April 10th. Roth Mkm reiterated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.50.
Gain Therapeutics Price Performance
Shares of NASDAQ:GANX opened at $1.65 on Wednesday. The company has a market cap of $70.37 million, a P/E ratio of -2.84 and a beta of 0.16. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics, Inc. has a 52 week low of $1.41 and a 52 week high of $4.34. The business has a fifty day simple moving average of $1.86 and a 200-day simple moving average of $2.32.
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). During the same period in the previous year, the company posted ($0.16) earnings per share. Equities research analysts forecast that Gain Therapeutics, Inc. will post -0.54 EPS for the current year.
About Gain Therapeutics
Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.
Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.
Featured Stories
- Five stocks we like better than Gain Therapeutics
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding GANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report).
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
